NR1I2 and ovarian carcinoma: Indeed, in epithelial ovarian cancer (OC) cells, PXR agonists, phthalate and P5, have been shown to induce the expression of CYP3A4 by binding to the CYP3A4 promoter, whereas paclitaxel and cisplatin increased the MDR1 expression and PXR binding to the MDR1 promoter [139].